Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dean F Bajorin

Showing results (91-100 of 169) with videos related to

Pageof 17
Sort By:
BJU International|April 5, 2013
Phase II study of everolimus in metastatic urothelial cancerMatthew I Milowsky, Gopa Iyer, Ashley M Regazzi, et al.
Clinical Genitourinary Cancer|September 4, 2017
Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder CancerAditya Bagrodia, Ranjit Sukhu, Andrew G Winer, et al.
European Urology Open Science|April 21, 2025
Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance)Brendan J Guercio, Karissa Whiting, Ronak H Shah, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2017
Transposon mutagenesis identifies chromatin modifiers cooperating with <i>Ras</i> in thyroid tumorigenesis and detects <i>ATXN7</i> as a cancer geneCristina Montero-Conde, Luis J Leandro-Garcia, Xu Chen, et al.
Nature Medicine|August 7, 2025
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trialMatthew D Galsky, Dean F Bajorin, Yoshihiko Tomita, et al.
The Journal of Pathology|May 7, 2011
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinomaHikmat A Al-Ahmadie, Gopa Iyer, Manickam Janakiraman, et al.
World Journal of Urology|February 25, 2019
Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomyMichael A Feuerstein, Leah Goldstein, Brieyona Reaves, et al.
Cancer Medicine|December 31, 2020
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tractMichal Sarfaty, Karissa Whiting, Min Yuen Teo, et al.
European Urology|March 3, 2023
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell ScoreMatthew D Galsky, Dean F Bajorin, Johannes Alfred Witjes, et al.
European Urology|June 7, 2017
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic TargetsEugene J Pietzak, Aditya Bagrodia, Eugene K Cha, et al.
Pageof 17

Showing results (91-100 of 169) with videos related to

Sort By:
Pageof 17
BJU International|April 5, 2013
Phase II study of everolimus in metastatic urothelial cancerMatthew I Milowsky, Gopa Iyer, Ashley M Regazzi, et al.
Clinical Genitourinary Cancer|September 4, 2017
Incidence and Effect of Thromboembolic Events in Radical Cystectomy Patients Undergoing Preoperative Chemotherapy for Muscle-invasive Bladder CancerAditya Bagrodia, Ranjit Sukhu, Andrew G Winer, et al.
European Urology Open Science|April 21, 2025
Circulating Tumor DNA and Response to Cisplatin-based Chemotherapy in Patients with Metastatic Urothelial Carcinoma Enrolled in CALGB 90601 (Alliance)Brendan J Guercio, Karissa Whiting, Ronak H Shah, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2017
Transposon mutagenesis identifies chromatin modifiers cooperating with <i>Ras</i> in thyroid tumorigenesis and detects <i>ATXN7</i> as a cancer geneCristina Montero-Conde, Luis J Leandro-Garcia, Xu Chen, et al.
Nature Medicine|August 7, 2025
Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trialMatthew D Galsky, Dean F Bajorin, Yoshihiko Tomita, et al.
The Journal of Pathology|May 7, 2011
Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high-grade urothelial carcinomaHikmat A Al-Ahmadie, Gopa Iyer, Manickam Janakiraman, et al.
World Journal of Urology|February 25, 2019
Propensity-matched analysis of patient-reported outcomes for neoadjuvant chemotherapy prior to radical cystectomyMichael A Feuerstein, Leah Goldstein, Brieyona Reaves, et al.
Cancer Medicine|December 31, 2020
A phase II trial of durvalumab and tremelimumab in metastatic, non-urothelial carcinoma of the urinary tractMichal Sarfaty, Karissa Whiting, Min Yuen Teo, et al.
European Urology|March 3, 2023
Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell ScoreMatthew D Galsky, Dean F Bajorin, Johannes Alfred Witjes, et al.
European Urology|June 7, 2017
Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic TargetsEugene J Pietzak, Aditya Bagrodia, Eugene K Cha, et al.
Pageof 17